Company intelligence / Profile preview

Evergreen Therapeutics, Inc.

Ownership: Private
Development stage: Phase 3

Overview

EG‑301 is notable as an oral medication targeting dry AMD with FDA clearance for phase II trials. It uses AI-driven mechanism assessment predicting anti-inflammatory and mitochondrial protective effects. This represents a first-in-class approach targeting dry AMD where no approved treatments currently exist globally

Therapeutic areas: OphthalmologyOncologyImmunologyRare Diseases
Modalities: Small molecule drugsAI-enabled drug discovery platform
Industry: Biotech

Drug pipeline

4 assets

EG-301

Phase 2

Indications: Not disclosed

3 more assets in the full pipeline.

Partnerships

Collaborations with academic institutionsPartnership with GPT-trainer for AI-based clinical protocol generation tool development

Beyond the preview

Go deeper on Evergreen Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Evergreen Therapeutics, Inc..